Prostate‐specific antigen density during dutasteride treatment for 1 year predicts the presence of prostate cancer in benign prostatic hyperplasia after the first negative biopsy (PREDICT study)

Objectives To prospectively evaluate the detection rate of prostate cancer, and to identify the risk factors of prostate cancer detection after a 1‐year administration of dutasteride and first negative prostate biopsy. Methods Patients with benign prostatic hyperplasia who presented high prostate‐specific antigen levels after the first negative prostate biopsy were administered 0.5 mg dutasteride daily for 1 year. They underwent a repeat...